

CASE REPORT

Open Access



Single coronary ostium with obstructive hypertrophic cardiomyopathy treated using the Morrow procedure: a case report

Xin Lv¹, Jianhua Li¹, Chuanzhen Liu^{1,2,3}, Ruyuan Wei¹, Lingwei Meng¹, Xiangjin Kong¹, Kaiming Wei¹, Guangqing Cao^{1*†} and Kai Liu^{1*†}

Abstract

Background: Hypertrophic cardiomyopathy is a commonly inherited heart disease. In addition, single coronary artery (SCA) is a rare congenital anomaly of the coronary arteries. And SCA concomitant with severe hypertrophic obstructive cardiomyopathy (HOCM) has seldom been reported in the literature. However, such cases have not been reported to be treated with the Morrow procedure.

Case presentation: Herein, we presented a case of a 64-year-old female diagnosed with a single left coronary artery with severe HOCM. The HOCM was treated with the Morrow procedure. The patient was discharged on the seventh postoperative day and was asymptomatic during the follow-up.

Conclusion: To our knowledge, this is the first study reporting a single left coronary artery with severe HOCM treated with the Morrow procedure. In addition, myocardial protection by cardioplegia antegrade perfusion was safe for the patient with SCA and HOCM.

Keywords: Single coronary artery, Hypertrophic obstructive cardiomyopathy, Morrow procedure, Cardiopulmonary bypass, Case report

Introduction

Hypertrophic cardiomyopathy (HCM) is a commonly inherited heart disease affecting 1 in 200 people (0.5%) [1]. Furthermore, single coronary artery (SCA) is a rare congenital coronary anomaly. The incidence of SCA is 0.024–0.066% [2]. In 1979, Lipton et al. proposed a method for categorizing single coronary anomalies, which was further improved by Yamanaka and Hobbs in 1990 [3]. SCA is more frequent when it coexists with other congenital anomalies, however, it could also

present as isolated congenital heart disease [3]. In addition, several cases of HCM coexisting with abnormal coronary origin have been reported [4–6]. However, severe hypertrophic obstructive cardiomyopathy (HOCM) with SCA treated with the Morrow procedure is not reported in the literature. Our current case report might provide a basis for the treatment of patients with coexisting HOCM and SCA.

Case presentation

A 64-year-old woman was admitted to the hospital because of chest tightness and shortness of breath. The physical examination revealed a grade III/VI systolic murmur with tremors in the third intercostal space of the left sternal border. The patient had no other significant clinical manifestations. A family history of hypertension was reported upon inquiry (her father and two older

[†]Kai Liu and Guangqing Cao contribute equally to this manuscript

*Correspondence: caogq001@163.com; 199662000265@sdu.edu.cn

¹ Department of Cardiovascular Surgery, Qilu Hospital of Shandong University, No.107, West Wenhua Road, Jinan 250012, Shandong, China
Full list of author information is available at the end of the article



sisters had hypertension) and our patient suffered from grade II hypertension (very high risk). The patient underwent left upper lobectomy for lung cancer 5 years ago, and the postoperative recovery was satisfactory. Holter electrocardiogram showed occasional atrial premature beats, frequent multi-source premature ventricular contractions, and ST-T changes (Fig. 1). Echocardiography showed that the left ventricular ejection fraction (LVEF) was 63%, and the basal part of the interventricular septum (IVS) was thickened (diastole, 20 mm). The hypertrophic myocardium protruded into the left ventricular outflow tract (LVOT) (diastole, Fig. 2A), which caused a severe obstruction of LVOT. The mitral valve regurgitation (severe) and systolic anterior motion (SAM) were observed in the systolic stage (Fig. 2B). In addition, the diastolic function of the left ventricle was reduced (Additional file 1: Movie 1). The echocardiograph showed that the systolic blood flow was in a specific direction from the left ventricle to the aorta with a peak velocity of 6.08 m/s, maximum transvalvular pressure of 147.73 mm Hg, and a mean pressure of 63.37 mm Hg (systole, Fig. 2C, Additional file 2: Movie 2). Coronary computed tomography angiography (CTA) showed significant stenosis of the

LVOT (Fig. 2D), and the right coronary artery (RCA) was absent. Three-dimensional (3D) -CTA imaging revealed the abnormal origin and course of the coronary artery (Fig. 3A, B). The subsequent conventional coronary angiography (CCA) examination further confirmed the diagnosis of SCA. The left coronary artery (LCA) originated from the left aortic sinus and spread throughout the heart. The great circumflex (CX) branch of the LCA supplied the area that the RCA supplies in the normal condition (Fig. 4). The patient was administered beta-blockers and calcium antagonists before admission but they had no significant effect. The patient had severe hypertrophy of the basal part of IVS, combined with SCA, and it was difficult to locate the target vessel, so the expected effect of alcohol radiofrequency ablation was poor. After the comprehensive evaluation of the preoperative condition and exclusion of the surgical contraindications, the Morrow procedure was performed under cardiopulmonary bypass (CPB). Anterograde perfusion of the aortic root was adopted during the surgery, and cardiac arrest was successfully induced. The intraoperative findings were consistent with the preoperative data: the myocardium with obvious hypertrophy of the basal part of




Fig. 1 The electrocardiogram preoperatively




Fig. 2 Echocardiography preoperatively the basal part of the interventricular septum (IVS) was thickened (A, arrow). SAM was obvious (B, arrow). Systolic blood flow image in a specific direction from the left ventricle to the aorta (C, arrow). Coronary CTA showing the hypertrophic myocardium clearly protrudes into the left ventricular outflow tract (LVOT) (D, arrow)

the IVS protruded into the LVOT (Fig. 5A), and RCA could not be detected (Fig. 5B). During the surgery, the hypertrophic myocardium was removed carefully, which unclogged the LVOT. About $3 \times 2 \times 0.8 \text{ cm}^3$ hypertrophic myocardium was cut longitudinally from 8 to 10 mm below the midpoint of the inferior margin of the right coronary valve to the junction of the left and right coronary valves. Further exploration showed that the mitral valve and subvalvular apparatus were normal. The patient was discharged on the seventh postoperative day. One day before discharge, the echocardiograph showed that the maximum transvalvular pressure between the LVOT and the aorta was 15 mm Hg, the mitral valve regurgitation was mild (Fig. 6A), the LVOT had been dredged (Fig. 6B), and the SAM had disappeared (Additional file 3: Movie 3). After more than 3 months of follow-up, the patient was asymptomatic.

Discussion and conclusions

HCM is a commonly inherited heart disease with an incidence of about 0.5% [1]. The clinical presentation of HCM is diverse and the pathophysiology is complex, yet therapeutic strategies are available and effective. HCM has transitioned from a rare and nearly incurable

disease to a common genetic disorder [7]. It is considered an important cause of arrhythmic cardiac arrest, heart failure, and atrial fibrillation (with embolic stroke) [8]. Clinical diagnosis is primarily based on unexplained left ventricular hypertrophy as determined using echocardiography or cardiovascular magnetic resonance imaging (MRI) [9].

SCA is a rare congenital developmental abnormality of the coronary artery with an incidence of 0.024–0.066%, where only one coronary artery emerges from the coronary ostium and supplies the entire heart [2]. In 1979, Lipton et al. proposed a classification of SCA malformations based on a large number of cases. The classification was further improved by Yamanaka and Hobbs in 1990, who divided it into different subtypes according to the origin and course of the coronary artery [3]. The first level of classification is right (R) and left (L) types, according to the origin of the SCA; the second level of classification is types I, II, and III, according to the course of the coronary branches. In type I, the artery runs along the anatomical route of the LCA or the RCA. The CX provides the posterior descending artery and runs in the posterior atrioventricular groove, and the CX branches supply the right atrium and the right ventricle; in the absence of the LCA,




Fig. 3 Three-dimensional coronary artery CTA imaging showing the abnormal origin and course of the coronary artery. The giant circumflex (CX) branch of the LCA supplied the right coronary artery blood supply area (A and B, arrow)

a large RCA is observed in the posterior atrioventricular groove, which extends to the anterior base of the heart, where it forms the left anterior descending artery (LAD). In type II, the other coronary artery originates proximal to the normally located one and passes through the base of the heart before reaching the normal part of the native coronary artery. In type III, the SCA originates from the right coronary sinus, while the LAD and left circumflex (LCX) branches originate from the common trunk. According to this classification, our patient belonged to the L-I type originating from the left coronary sinus.

HCM and coronary artery abnormalities are considered to be the leading causes of exercise-related cardiac arrest, especially in young adults [10]. Although SCA can occur as isolated congenital heart disease, its incidence increases when it coexists with certain other congenital anomalies. Congenital anomalies coexisting with SCA include coronary aneurysm [11], coronary arteriovenous fistula [12], ventricular septal defect [13], transposition of great vessels [14], patent foramen ovale [15], tetralogy of Fallot [16], trunk arteriosus [17], patent ductus arteriosus [18], and bicuspid aortic valve [19]. In addition, several cases of HCM coexisting with abnormal coronary origin have been reported [4–6]. Although cases of HCM with

SCA are reported [20], ours is the first report where such a case was treated with the Morrow procedure. The current report suggests that the Morrow procedure is an effective treatment of HOCM with SCA.

The treatment of HOCM is mainly to relieve symptoms and prevent sudden death. For symptomatic patients, negative inotropic drugs including beta-blockers and calcium antagonists can relieve symptoms, while for drug-refractory patients, surgical treatment, including Alcohol septal ablation (ASA) and myectomy, should be considered [21]. Our patient was administered beta-blockers and calcium antagonists before admission but they had no significant effect. The LVOT differential pressure was large, and the patient was symptomatic. Studies have shown that Cibenzoline treatment significantly reduces all cardiovascular complications and death due to left ventricular heart failure and may be a promising treatment for HOCM patients [22]. ASA is an effective method for the treatment of HOCM, and its safety and efficacy have been confirmed by several studies; however, certain patients, especially those with severe basal thickening, do not benefit from the treatment. The patient had severe hypertrophy of the basal part of IVS, combined with SCA, and it was difficult to locate the target vessel,




Fig. 4 Coronary angiography (DSA) showing a single coronary artery(SCA).Anterior descending artery (LAD) (A and B, arrow).The giant circumflex (CX) branch of the LCA (C and D, arrow)





Fig. 5 Imaging of the operation.The hypertrophic myocardium of the basal part of the IVS (A, arrow).A single left coronary ostium (B, white arrow). There is no right coronary artery opening in the right sinus of aortic sinus (B, black arrow)



so the expected effect of ASA was poor. Furthermore, HCM patients with left ventricular systolic dysfunction (defined as left ventricular ejection fraction < 50%) have a poor prognosis [23]. The LVEF of our patient was 0.63, and after the comprehensive evaluation of the preoperative condition and exclusion of the surgical contraindications, the Morrow procedure under CPB was identified as the best choice. During the Morrow procedure, the extent of resection of hypertrophic myocardium should be determined according to the actual situation observed during the surgery, not only to relieve the SAM but also to avoid serious complications such as third-degree conduction block and left ventricular rupture caused by excessive myocardial resection.

Various rare courses of SCA can lead to accidental ligation or damage to important blood vessels during cardiac surgery. Therefore, the cardiac surgeon and coronary angiographer should be familiar with the presence and anatomy of this congenital anomaly. Because of the rarity of this condition and the complications during surgery, it is recommended that CCA should be performed before cardiac surgery. In addition, SCA should also be

paid attention to during cardiopulmonary bypass surgery, because the effect of myocardial protection was related to the strategy of cardioplegia perfusion in such patients. In our case, the CCA and echocardiographic imaging data of the patient were discussed in detail before the surgery, which suggested that there was no obvious abnormality of the aortic valve. It was agreed that anterograde perfusion in the aortic root would be safe and effective, and direct perfusion of the SCA would be performed if necessary. The current report is only for individual cases, patients with the same disease need individual solutions.

Abbreviations

HCM: Hypertrophic cardiomyopathy; SCA: Single coronary artery; HOCM: Hypertrophic obstructive cardiomyopathy; LVEF: Left ventricular ejection fraction; IVS: The interventricular septum; LVOT: Left ventricular outflow tract; SAM: Systolic anterior motion; CTA: Computed tomography angiography; RCA: Right coronary artery; CCA: Conventional coronary angiography; LCA: Left coronary artery; CX: Circumflex; CPB: Cardiopulmonary bypass; LAD: Anterior descending artery; LCX: Left circumflex; ASA: Alcohol septal ablation.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13019-022-02084-2>.

Additional file 1: Movie 1. Preoperative Echocardiography showed the LVOT was severely obstructed, and the SAM was obvious

Additional file 2: Movie 2. Preoperative Echocardiography showed systolic blood flow accelerated in a specific direction from the left ventricle to the aorta and the severe mitral valve regurgitation

Additional file 3: Movie 3. Postoperative echocardiography showed LVOT blood flow is unobstructed and the SAM disappeared

Acknowledgements

We express our sincere thanks to Dr. Xiquan Zhang and Dr. Shuming Wu for thoughtful discussion and valuable comments.

Author contributions

LX and LJH collected the data. LX and LCZ wrote the manuscript. WRY, MLW, KXJ, and WKM analysed the patient data. CGQ was Chief surgeon. LJH and LX was assistant. LK was perfusionist. The authors read and approved the final manuscript.

Funding

This work was supported by The National Natural Science foundation of China (NO.81600293), the Key Research and Development Projects of Shandong Province (NO.2018GSF121007) and the Shandong Provincial Natural Science Foundation of China (No. ZR2021MH221, ZR2021MH244).

Availability of data and materials

As this paper is a case report, all data generated or analysed are included in this article.

Declarations

Ethics approval and consent to participate

This study was approved by the Ethics Committee of Qilu Hospital of Shandong University, Jinan, China. Written informed consent was obtained from the patient reported in this study. All methods were performed in accordance with the Declaration of Helsinki.

Consent for publication

The authors confirm that written consent for submission and publication of this case report, including the images and the associated movie, has been obtained from the patient. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests

Authors have no competing interests associated with this study.

Author details

¹Department of Cardiovascular Surgery, Qilu Hospital of Shandong University, No.107, West Wenhua Road, Jinan 250012, Shandong, China. ²Shandong University, Jinan 250061, Shandong, China. ³Pantheum Biotechnology Co., Ltd, Shandong, Jinan, China.

Received: 7 April 2022 Accepted: 10 December 2022

Published online: 28 December 2022

References

- Bonaventura J, Polakova E, Vejtasova V, Veselka J. Genetic testing in patients with hypertrophic cardiomyopathy. *Int J Mol Sci*. 2021;22(19):10401.
- Turkmen S, Yolcu M, Sertcelik A, Ipek E, Dokumaci B, Batyraliev T. Single coronary artery incidence in 215,140 patients undergoing coronary angiography. *Folia Morphol*. 2014;73(4):469–74.
- Desmet W, Vanhaecke J, Vrolix M, Van de Werf F, Piessens J, Willems J, de Geest H. Isolated single coronary artery: a review of 50,000 consecutive coronary angiographies. *Eur Heart J*. 1992;13(12):1637–40.
- Moza A, Prashar R, Bawany M. Anomalous origin of right coronary artery associated with hypertrophic obstructive cardiomyopathy. *Am J Med Sci*. 2011;342(4):341–2.
- Georgekutty J, Cross RR, Rosenthal JB, Heath DM, Sinha P, John AS. Anomalous left coronary artery from the right coronary cusp with gene positive apical hypertrophic cardiomyopathy: a case report and literature review. *Cardiol Young*. 2014;24(3):397–402.
- Villa AD, Sammut E, Nair A, Rajani R, Bonamini R, Chiribiri A. Coronary artery anomalies overview: the normal and the abnormal. *World J Radiol*. 2016;8(6):537–55.
- Tuohy CV, Kaul S, Song HK, Nazer B, Heitner SB. Hypertrophic cardiomyopathy: the future of treatment. *Eur J Heart Fail*. 2020;22(2):228–40.
- Falascioni G, Pannone L, Slavich M, Margonato A, Fragasso G, Spoladore R. Atrial fibrillation in hypertrophic cardiomyopathy: pathophysiology, diagnosis and management. *Am J Cardiovasc Dis*. 2020;10(4):409–18.
- Geske JB, Ommen SR, Gersh BJ. Hypertrophic cardiomyopathy: clinical update. *JACC Heart Fail*. 2018;6(5):364–75.
- Giese EA, O'Connor FG, Brennan FH, Depenbrock PJ, Oriscello RG. The athletic preparticipation evaluation: cardiovascular assessment. *Am Fam Phys*. 2007;75(7):1008–14.
- Bolognesi R, Tsialtas D, Barbaresi F, Manca C. Single coronary artery-right ventricular fistula with a partially thrombosed large aneurysm of its proximal tract in a 66-year-old man. *Eur Heart J*. 1994;15(12):1720–4.
- Soon KH, Selvanayagam J, Bell KW, Tang SH, Pereira J, Chan W, Lim YL. Giant single coronary system with coronary cameral fistula diagnosed on MSCT. *Int J Cardiol*. 2006;106(2):276–8.
- Favero L, La Vecchia L, Ottani F, Martini M, Vincenzi P, Fontanelli A. Single coronary artery associated with perimembranous ventricular septal defect. *Ital Heart J Off J Ital Fed Cardiol*. 2003;4(11):813–5.
- Güven H, Billadello J, Beardslee M. An isolated single coronary artery supplying the entire myocardium in a patient with congenitally corrected transposition of the great vessels. *Heart*. 2004;90(12):1410.
- Ermis E, Demirelli S, Korkmaz AF, Sahin BD, Kantarci A. An isolated single L-II type coronary artery anomaly: a rare coronary anomaly. *Intractable Rare Dis Res*. 2015;4(4):203–6.
- Jaswal V, Thingnam SKS, Kumar V, Patel R, Munirathinam GK, Toshkhani D. A single coronary artery with left circumflex artery crossing right ventricular outflow tract in tetralogy of fallot with absent left pulmonary artery. *J Cardiovasc Thorac Res*. 2021;13(1):87–9.
- Thankavel PP, Brown PS, Nugent AW. High-takeoff single coronary artery with intramural course in truncus arteriosus: prospective echocardiographic identification. *Pediatr Cardiol*. 2013;34(6):1517–9.
- Hugues N, Dommerc C, Pretre R. Anomalous origin of a single coronary artery from the pulmonary artery associated with patent ductus arteriosus. *Cardiol Young*. 2020;30(7):1043–5.
- Ishida N, Shimabukuro K, Matsuno Y, Ogura H, Takemura H. Single coronary artery with bicuspid aortic valve stenosis and aneurysm of the ascending aorta: report of a case. *Surg Today*. 2014;44(3):550–2.
- Chow B, Ling M, Asch K. Single coronary artery in a patient with apical variant hypertrophic cardiomyopathy. *Can J Cardiol*. 2009;25(6):e205.
- Sigwart U. Therapeutic myocardial infarction for hypertrophic obstructive cardiomyopathy: Is it appropriate? *Circulation*. 2019;140(1):11–2.
- Hamada M, Shigematsu Y, Ikeda S, Ohshima K, Ogimoto A. Impact of cibenzoline treatment on left ventricular remodeling and prognosis in hypertrophic obstructive cardiomyopathy. *ESC Heart Fail*. 2021;8(6):4832–42.
- Marstrand P, Han L, Day SM, Olivetto I, Ashley EA, Michels M, Pereira AC, Wittekind SG, Helms A, Saberi S, et al. Hypertrophic cardiomyopathy with left ventricular systolic dysfunction: insights from the SHaRe Registry. *Circulation*. 2020;141(17):1371–83.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

